---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-000381"
form_type: "8-K"
ticker: "NAGE"
cik: "0001386570"
company_name: "Niagen Bioscience, Inc."
filed_at: "2023-01-05T23:59:59+00:00"
generated_at: "2026-06-20T19:28:58.564884+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ChromaDex names Brianna Gerber CFO effective Jan 1, 2023; salary $325K

## Summary
- Brianna Gerber appointed CFO after serving as interim CFO since August 2022.
- Base salary $325,000; discretionary target bonus 50% of base; LTI opportunity 70% of base (Black-Scholes).
- Termination w/o cause/good reason: 12-mo salary continuation, pro-rata bonus, COBRA (12 mos), accelerated vesting.
- CEO Fried highlights her role in shepherding ChromaDex to EBITDA positive business with fiscal responsibility.

## SEC filing metadata
- accession: 0001628280-23-000381
- form_type: 8-K
- ticker: NAGE
- cik: 0001386570
- company_name: Niagen Bioscience, Inc.
- filed_at: 2023-01-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1386570/000162828023000381/0001628280-23-000381-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1386570/000162828023000381/cdxc-20230103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-000381
- JSON: https://secwatch.observer/filing/0001628280-23-000381.json
- Plain text: https://secwatch.observer/filing/0001628280-23-000381.txt

## Key facts
- Executive change
  Brianna Gerber was appointed as Chief Financial Officer at Niagen Bioscience, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: appointed Brianna Gerber as Chief Financial Officer of the Company, effective as of January 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1386570/000162828023000381/0001628280-23-000381-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.